T. Rowe Price Associates’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $480K | Buy |
|
|||||
|
2025
Q1 | $313K | Buy |
|
|||||
|
2024
Q4 | $459K | Sell |
|
|||||
|
2024
Q3 | $12M | Sell |
|
|||||
|
2024
Q2 | $27.9M | Sell |
|
|||||
|
2024
Q1 | $44.7M | Sell |
|
|||||
|
2023
Q4 | $55.9M | Sell |
|
|||||
|
2023
Q3 | $64.8M | Sell |
|
|||||
|
2023
Q2 | $84M | Buy |
|
|||||
|
2023
Q1 | $69.7M | Sell |
|
|||||
|
2022
Q4 | $67.3M | Buy |
|
|||||
|
2022
Q3 | $97.2M | Sell |
|
|||||
|
2022
Q2 | $106M | Sell |
|
|||||
|
2022
Q1 | $161M | Buy |
|
|||||
|
2021
Q4 | $248M | Sell |
|
|||||
|
2021
Q3 | $315M | Sell |
|
|||||
|
2021
Q2 | $403M | Buy |
|
|||||
|
2021
Q1 | $187M | Buy |
|
|||||
|
2020
Q4 | $115M | Buy |
|
|||||
|
2020
Q3 | $29M | Buy |
|
|||||
|
2020
Q2 | $28.4M | Buy |
|
|||||
|
2018
Q3 | – | Sell |
|
|||||
|
2018
Q2 | $280K | Sell |
|
|||||
|
2018
Q1 | $1.24M | Buy |
|